Se connecter Inscription gratuite

Affimed N.V Revenu Y/Y

Quel est le Revenu Y/Y de Affimed N.V?

Le Revenu Y/Y de Affimed N.V. est -16.00%

Quelle est la définition de Revenu Y/Y?

La croissance annuelle des revenus des trois dernières années correspond à la croissance moyenne des revenus d’une année sur l’autre au cours des trois dernières années.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Revenu Y/Y des entreprises dans Health Care secteur sur NASDAQ par rapport à Affimed N.V

Que fait Affimed N.V?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Entreprises avec revenu y/y similaire à Affimed N.V